Lilly, Regor Therapeutics Group enter into strategic collaboration

By The Science Advisory Board staff writers

December 13, 2021 -- Eli Lilly and Regor Therapeutics Group have entered into a multiyear research collaboration and licensing agreement to discover, develop, and commercialize novel therapies for metabolic disorders, including obesity and diabetes. The groups will leverage Regor's computer accelerated rational discovery platform.

Under the terms of the agreement, Lilly will have a license to select Regor's intellectual property, with an option to extend the license. Lilly is responsible for clinical development, manufacturing, and commercialization worldwide, except for the People's Republic of China, Macau, Hong Kong, and Taiwan, where Regor will maintain these rights and responsibilities.

In addition, the agreement allows Lilly and Regor to leverage both parties' existing compounds and technologies globally. Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor, subject to the parties entering into standard equity agreements. Regor is also eligible to receive up to $1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development, and commercial milestones, as well as tiered royalties from sales resulting from the agreement.

The transaction will be reflected in Lilly's reported results and financial guidance, according to generally accepted accounting principles (GAAP). There will be no change to Lilly's 2021 non-GAAP earnings per share guidance from this transaction, Lilly stated.

Eli Lilly, Lycia partner to develop new LYTAC degraders
Lilly and Lycia Therapeutics have signed a multiyear deal to develop and commercialize new lysosomal targeting chimera (LYTAC) degraders based on Lycia's...
Lilly Bio-Medicines splits into neuroscience, immunology units
Eli Lilly has divided Lilly Bio-Medicines into neuroscience and immunology business units. The company said the move will help it introduce "breakthrough...
Lilly to acquire Protomer Technologies for $1B
Eli Lilly will acquire private biotechnology firm Protomer Technologies for an estimated $1 billion.
Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's...
Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter